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PRESCRIPTION PATTERNS AND EXPENDITURE OF ANTI-TNG AGENTS 
IN RHEUMATOID PATIENTS IN TAIWAN
Chiu Y
Changhua Christian Hospital, Changhua City, Changhua County, Taiwan
OBJECTIVES: There was still no pharmacoepidemiologic study of tumor necrosis 
factor antagonist (Anti-TNF) in Taiwan. We analysis the drug cost and prescription 
pattern of anti-TNF agents, and the change of prescription pattern of tradition disease-
modiﬁed anti-rheumatic drug (DMARD) when anti-TNF used. METHODS: This 
study utilizes National Health Insurance Database which cover more than 99% popu-
lation in Taiwan. We analysis of the direct medical cost for RA patients from 1996 
to 2007, and prescribe pattern of disease-modiﬁed anti-rheumatic drug (DMARD) and 
anti-TNF agents. RESULTS: The cost of anti-TNF agents accounted for 25% of total 
direct cost. But there was only about 5% RA patients been treated with this drug in 
Taiwan. The mean age of anti-TNF user was younger, but sex distribution seen no 
statistically difference in user and non-user group. In patients with anti-TNF use, the 
combined use of DMARD was decreased markedly. However, there is still some 
proportion of anti-TNF user have full dosage of DMARD treatment which suggest 
the possibility of inadequate response to anti-TNF agents in the population CONCLU-
SIONS: The percentage of anti-TNF agent use in RA patients is relative low in Taiwan. 
Some proportion of anti-TNF user still need full dosage DMARD and it may suggest 
the possibility of inadequate to anti-TNF agents in this group.
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OBJECTIVES: Bisphosphonates are effective in reducing the risk of fractures and are 
used to prevent and treat osteoporosis. Between 2000 and 2007, new bisphosphonate 
chemicals and formulations were introduced into Canada, and new evidence and 
practice guidelines emerged. This analysis provides insight into bisphosphonate use 
among seniors during this time period. METHODS: Claims level data from the 
National Prescription Drug Utilization Information System (NPDUIS) Database were 
analyzed for seniors on public drug programs in six Canadian provinces between 
2001–2002 and 2006–2007. The analysis looked at trends in bisphosphonates use by 
age and sex, by chemical, and by formulation (daily and weekly therapy). The analysis 
also looked at the medication possession ratio (MPR) for bisphosphonate users, a 
surrogate measure for compliance with therapy. RESULTS: The age–sex standardized 
rate of bisphosphonate use across all provinces increased from 8.9% in 2001–2002 
to 12.9% in 2006–2007. The rate of use among females (20.4%) was more than six 
times the rate of use among males (3.3%). In 2006–2007, alendronate had the highest 
rate of use, at 5.9%, followed by etidronate at 4.9% and risedronate at 2.9%. There 
was a signiﬁcant shift from the use of daily to the use of weekly therapy. The rate of 
use of weekly therapy increased from 0.1% to 8.4%, while use of daily therapy dropped 
from 9.3% to 5.3%. The surrogate measure for compliance showed little difference 
between patients on daily and weekly therapy. CONCLUSIONS: This analysis pro-
vides insight into how the introduction of new chemicals and dosage formulations 
affected bisphosphonate use among seniors between 2001–2002 and 2006–2007. 
There was a signiﬁcant shift to the use of newer chemicals and weekly therapies. There 
was little difference in compliance between daily and weekly bisphosphonate users.
PMS53
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OBJECTIVES: Traditional nonsteroidal anti-inﬂammatory drug (tNSAID) utilisation 
has recently increased considerably in the elderly in spite of their higher gastrointes-
tinal (GI) toxicity and an increasing body of evidence pointing to similar cardiovascu-
lar (CV) safety compared to celecoxib. The objective is to describe the proﬁle of 
patients who used celecoxib and tNSAIDs between April 1, 2005 and March 31, 2007 
(post- rofecoxib withdrawal period) versus April 1, 2002 and March 31, 2004 (pre-
rofecoxib withdrawal period) in Quebec, Canada. METHODS: Data were obtained 
from the physician and medication claims databases of the Quebec Health Insurance 
Agency. All patients 50 years of age and older who used celecoxib or tNSAIDs during 
the study periods were included. Patients were categorized by GI, CV, congestive heart 
failure (CHF) and renal risk factors and four risk categories were considered (low, 
moderate, high, and very high) in each condition. RESULTS: The numbers of patients 
on celecoxib were 145,596 and 178,714 in the post- vs. pre-period, while those on 
tNSAIDs were 249,433 and 120,809, respectively. Logistic regression models revealed 
that users of celecoxib vs. tNSAIDs were more likely to have higher GI risk levels in 
both periods [post-period (vs. low risk): very high 1.79 (95%CI: 1.63, 1.97), high 
1.76 (1.71, 1.81) and moderate 1.30 (1.27, 1.33)]. While users of celecoxib had higher 
CV risk levels in the pre-period compared to tNSAIDs, their very high CV risk level 
in the post-period was lower [post-period (vs. low risk): very high 0.85 (0.81, 0.89), 
high 1.13 (1.10, 1.16) and moderate 1.15 (1.12, 1.17)]. In both periods, the impact 
of CHF and renal risks on the choice of celecoxib vs. tNSAIDs appears to be less 
important. CONCLUSIONS: Currently, patients at very high CV risk seem to be less 
likely to receive celecoxib vs. tNSAIDs, while those with GI risk factors seem more 
likely to receive celecoxib.
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OBJECTIVES: To examine racial and ethnic disparities in receiving total knee replace-
ment surgery among eligible patients. METHODS: Using a nationally-representative 
inpatient care dataset, the HCUP National Inpatient Sample, from 1998 to 2007, we 
had an available sample of 809,750 Caucasians, 74,869 African- Americans, 48,010 
Latinos, 8,976 Asians, and 2,554 Native Americans who were eligible for total knee 
replacement surgery based on their ICD 9 codes. Multivariable logistic regressions 
were used to estimate the racial and ethnic disparities in the rates of actually receiving 
knee replacement surgery among these eligible subjects. Blinder-Oaxaca decomposi-
tion techniques were employed to determine the extent to which racial and ethnic 
disparities reﬂect differences in observable population characteristics versus unob-
served heterogeneity across racial and ethnic groups. RESULTS: Approximately 90% 
of Caucasians, 70% of African-Americans, 75% of Latinos and Asians, and 83% of 
Native Americans who were eligible to receive total knee replacement surgery actually 
did receive it. These disparities persisted in the multivariable analyses. Compared to 
Caucasians, the odds of having the total knee surgery was 0.46 for African Americans 
(p < 0.0001), 0.49 for Latinos (p < 0.0001), 0.45 for Asians (p < 0.0001), and 0.67 
for Native Americans (p < 0.0001). The Blinder-Oaxaca decomposition showed that 
39%–59% of the observed differences in the racial and ethnic disparities in receiving 
the total knee replacement surgery can be explained by observed population charac-
teristics, most important of which are differences in age and health insurance coverage 
by race and ethnicity. CONCLUSIONS: Substantive racial and ethnic disparities exist 
in total knee replacement surgery among the eligibles. Observable population charac-
teristics account for most of the differences, with age and health insurance key factors 
driving racial and ethnic disparities in receiving this surgery. Unobserved heterogene-
ity, which may include physician-patient relationships, mistrust, and cultural factors, 
are also related to these disparities.
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OBJECTIVES: To examine racial and ethnic disparities in receiving total hip replace-
ment surgery among eligible patients. METHODS: Using a nationally-representative 
inpatient care dataset, the HCUP National Inpatient Sample, from 1998 to 2007, we 
had an available sample of 317,766 Caucasians, 34,339 African Americans, 18,138 
Latinos, 3,805 Asians, and 923 Native Americans who were eligible for the total hip 
replacement surgery. Multivariable logistic regressions were used to estimate the racial 
and ethnic disparities of actually receiving the replacement surgery among eligible 
patients. The Blinder-Oaxaca decomposition techniques were employed to determine 
the extent to which disparities reﬂect differences in observable population character-
istics versus unobserved heterogeneity across racial and ethnic groups. RESULTS: 
Approximately 77% of Caucasians, 51% of African Americans, 46% of Latinos, 51% 
of Asians, and 56% of Native Americans who were eligible to receive total hip replace-
ment surgery actually received it. These disparities persisted in the multivariable 
regressions. Compared to Caucasians, the odds of having total hip replacement surgery 
was 0.52 for African Americans (p < 0.0001), 0.41 for Latinos (p < 0.0001), 0.44 for 
Asians (p < 0.0001), and 0.47 for Native Americans (p < 0.0001). The Blinder-Oaxaca 
decomposition method revealed that 43%–53% of the observed differences between 
Caucasians vs. African Americans, Latinos, and Asians in receiving total hip replace-
ment surgery can be explained by observed population characteristics, among which 
differences in age, health insurance coverage, and gender are the major factors associ-
ated with these disparities. In contrast, observed population characteristics only 
explained 3% of the differences between Caucasians vs. Native Americans. CONCLU-
SIONS: Substantive racial and ethnic disparities exist in total hip replacement surgery. 
Observable population characteristics account for most of these differences (with the 
exception of Native Americans), with age and health insurance being key factors. 
Unobserved heterogeneity such as unobserved physician-patient relationships, mis-
trust, and cultural factors, is also related to the disparities, especially for the disparities 
between Caucasians and Native Americans.
